Scale-up of HIV Viral Load Monitoring — Seven Sub-Saharan African Countries
 |
| MMWR Weekly Vol. 64, No. 46 November 27, 2015 |
| PDF of this issue |
Scale-up of HIV Viral Load Monitoring — Seven Sub-Saharan African Countries
Weekly
November 27, 2015 / 64(46);1287-1290, MD1; , PhD1; , PhD1; , PhD1; , MD2; MS3; , MD1; , MBBCh4; , MBBS5; , MD6; , PhD7; , MD6; , MD5; , MD1; , MPhil8; , MD7; , Sc.D4; 9; , MBChB6; , MMed10; , MMed6; 11; , MBChB6; , PhD12; , DSc5; 2; , MD5;, MBBCh4; , PhD3; , PhD1
To achieve global targets for universal treatment set forth by the Joint United Nations Programme on human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) (UNAIDS), viral load monitoring for HIV-infected persons receiving antiretroviral therapy (ART) must become the standard of care in low- and middle-income countries (LMIC) (1). CDC and other U.S. government agencies, as part of the President's Emergency Plan for AIDS Relief, are supporting multiple countries in sub-Saharan Africa to change from the use of CD4 cell counts for monitoring of clinical response to ART to the use of viral load monitoring, which is the standard of care in developed countries. Viral load monitoring is the preferred method for immunologic monitoring because it enables earlier and more accurate detection of treatment failure before immunologic decline. This report highlights the initial successes and challenges of viral load monitoring in seven countries that have chosen to scale up viral load testing as a national monitoring strategy for patients on ART in response to World Health Organization (WHO) recommendations. Countries initiating viral load scale-up in 2014 observed increases in coverage after scale-up, and countries initiating in 2015 are anticipating similar trends. However, in six of the seven countries, viral load testing coverage in 2015 remained below target levels. Inefficient specimen transport, need for training, delays in procurement and distribution, and limited financial resources to support scale-up hindered progress. Country commitment and effective partnerships are essential to address the financial, operational, technical, and policy challenges of the rising demand for viral load monitoring.
In 2014, UNAIDS launched "90-90-90" goals to increase to 90% by 2020 the proportion of persons living with HIV infection who know their status, the proportion of persons living with HIV infection receiving ART, and the proportion of persons living with HIV infection on ART who have achieved viral suppression (defined as HIV RNA concentration below the threshold needed for detection on a viral load assay) (1). Increasing viral load monitoring for ART patients will require lowering costs associated with viral load testing and improving access in LMIC. A global diagnostic access initiative was launched in 2014 by UNAIDS, which challenged the global community to work with manufacturers to provide reasonably priced viral load testing, reducing the price of test kits to as low as $10 per test (2).
By the first quarter in 2015, 15 million persons living with HIV infection were on ART globally (3). Recent results from the Strategic Timing of Anti-Retroviral Treatment trial demonstrated that early treatment reduced morbidity and mortality in persons with HIV infection (4). As a result, a greater demand for early ART initiation and viral load testing exists (4). In sub-Saharan Africa, where 11 million persons living with HIV infection are receiving ART (3), an estimated six million ART patients do not have access to viral load testing (5). Certain countries in sub-Saharan Africa have adopted the 2013 WHO recommendation to use routine viral load testing for monitoring treatment (6). This report highlights the initial successes and challenges of viral load monitoring as a national strategy in seven of these countries.
Côte d'Ivoire, Kenya, Malawi, Namibia, South Africa, Tanzania, and Uganda are in various stages of scaling up viral load monitoring. Routine laboratory and clinical data were collected by the ministries of health and CDC personnel from each country's laboratory database on the total number of ART patients, the total number of viral load tests, the number of viral load tests with laboratory-confirmed viral suppression, and the established target number of viral load tests for 2015 and 2016. In addition, information was collected from the laboratory database on the time from sample collection to return of results to the referring clinic. The directors of the national reference laboratories and CDC laboratory liaisons were asked to report operational challenges and successes to viral load monitoring scale-up. The pre–scale-up period was defined as the year before each government scaled up routine viral load monitoring for their country and the post–scale-up period as the time from scaling up routine viral load monitoring until June 2015.
South Africa initiated viral load monitoring in 2004 and scale-up for routine viral load monitoring in 2014 on the basis of the 2013 WHO HIV treatment recommendations. In Kenya, Malawi, Namibia, and Uganda, the pre–scale-up period was 2013, and the post–scale-up period was 2014–2015. For comparison purposes, the pre–scale-up period for South Africa was defined as 2013 and the post–scale-up period as 2014–2015. For Côte d'Ivoire and Tanzania, the pre–scale-up period was 2014 and the post–scale-up period was 2015. In 2015, the number of ART patients was highest in South Africa (2,951,159) and lowest in Namibia (131,721) (Table 1). In 2015, the number of ART patients with one or more viral load test ranged from 3,687 (Côte d'Ivoire) to 2,119,890 (South Africa). Among countries initiating routine viral load monitoring scale-up in 2014, the proportion of ART patients with viral load tests in the pre– and post–scale-up period increased from 8% to 38% in Kenya, 6% to 11% in Malawi, 54% to 95% in Namibia, and 5% to 10% in Uganda (Table 1). A slight increase was seen in South Africa between the pre– and post–scale-up periods, from 72%–75%. In the countries where routine viral load monitoring scale-up occurred in 2015, the proportion of ART patients with viral load tests was low and unchanged between the pre– and post–scale-up periods in Tanzania (from 2% to 3%) and in Côte d'Ivoire (from 4% to 3%).
In 2015, the proportion of viral load tests with viral suppression in countries initiating routine viral load monitoring scale-up in 2014 was 78% in South Africa, 83% in Kenya, 84% in Malawi, 86% in Namibia, and 94% in Uganda (Table 1). Between the pre– and post–scale-up periods, viral suppression levels increased by 30% in Kenya and 16% in Namibia, and changed little in Malawi, South Africa, and Uganda. In comparison, suppression levels decreased in Tanzania (from 80% to 72%) and in Côte d'Ivoire (from 66% to 53%) in 2015 (Table 1).
During the post–scale-up period, the average time from specimen collection to return of results to the referring clinic varied, from 3 days in South Africa to 31 days in Kenya (Table 1). Turnaround times increased between the pre– and post–scale-up periods in Kenya and Malawi, remained unchanged in South Africa and Côte d'Ivoire, and decreased in Namibia, Tanzania, and Uganda. Laboratory results were returned to clinics using various methods, including short message service printers, laboratory information systems, courier services, email, and use of specimen transport networks to reduce turnaround times.
Difficulties in specimen transport and lack of trained laboratory personnel were among the most common challenges reported in viral load monitoring scale-up (Table 2). Five countries reported success with innovations in laboratory information management systems and use of high-throughput viral load platforms. Four countries reported that strong partnerships and use of specimen referral networks, such as networks for transporting specimens from health facilities to referral laboratories for early infant HIV diagnosis, were integral to success.
The majority of countries did not achieve the targets established by each government for routine viral load monitoring in 2015, highlighting the efforts needed in sub-Saharan Africa to improve viral load monitoring coverage rates to achieve the 90–90–90 objectives. The forecasted viral load testing gap for 2016 could be narrowed in some countries with implementation of strategies, including policies on laboratory service provision, use of automated high-throughput and polyvalent platforms, introduction of point-of-care viral load technologies, increasing work-flow efficiencies, and improving laboratory infrastructure.
Discussion
The majority of countries in this report are in early stages of initiating viral load testing as a national monitoring strategy for patients on ART. Five countries reported high levels of viral load suppression, which has been previously reported (7). The increase in viral load testing for Kenya and Namibia was associated with an increase in viral suppression levels; however, minimal change in viral suppression occurred in Malawi, and there was a decrease in viral suppression in Côte d'Ivoire and Tanzania. One possible explanation for increases in viral load suppression following increases in viral load testing is that with scale-up in viral load testing, follow-up of patients is more frequent, which can reinforce ART adherence and lead to an overall improvement in viral load suppression. In other settings where a decrease in viral load suppression was noted, the increase in viral load testing might have overwhelmed constrained resources, leading to a backlog in performing viral load tests, and preventing the timely use of results for patient management, which might ultimately result in a decrease in viral load suppression.
Numerous health system challenges were encountered as viral load monitoring scale-up was initiated, including difficulties with specimen transport, equipment breakdown, personnel shortages, and weak laboratory information management systems and laboratory infrastructure. Similar challenges have been reported with the expansion of early infant diagnosis of HIV-infected children (8). Furthermore, even in programs with routine viral load monitoring, a substantial proportion of patients with confirmed virologic failure on first-line ART are not being appropriately switched to second-line ART (9). Therefore, as viral load monitoring is being scaled up, management of patient results should also be addressed. Novel approaches are needed, including alternative methods to improve the quality and efficiency of specimen transport, the use of electronic tools for transmission of results, and efficient use of human resources. Continuous quality improvement in laboratory systems is needed to meet the rising demand for viral load testing (10). Workforce development should be optimized through training of health care providers to use viral load results appropriately for patient management. Appropriate use of viral load results is important to the impact of increasing viral load testing. As scale-up progresses, a robust monitoring and evaluation system is needed to determine the effectiveness of viral load monitoring scale-up.
The findings in this report are subject to at least four limitations. First, because it was not possible to disaggregate results by patient and timing of test, the direct impact of viral load monitoring on patient management could not be assessed. Second, lower viral suppression rates observed during the pre–scale-up period might not be representative of all persons on ART but might reflect targeted testing of persons who were suspected to be failing treatment. Third, the results for pediatric and adult patients might differ; however, pediatric data were unavailable for six of the seven countries. Finally, specific patient information was not collected to inform the findings on the proportion of patients who achieved viral load suppression.
The initial experience of viral load scale-up in these seven sub-Saharan African countries provides evidence that routine viral load monitoring for ART patients in this region can be achieved. Considerable investments will be required to improve laboratory systems for service delivery and strengthen the overall health systems infrastructure. Effective partnerships and substantial financial, operational, technical, and political commitments are needed for successful scale-up. Routine viral load monitoring and usage of results to inform clinical decisions for ART patients in sub-Saharan Africa will lead to substantial improvements in health outcomes moving toward epidemic control of HIV.
1Center for Global Health, Division of Global HIV/AIDS, CDC, Atlanta, Georgia; 2Center for Global Health, Division of Global HIV/AIDS, CDC, Windhoek, Namibia;3Center for Global Health, Division of Global HIV/AIDS, CDC, Abidjan, Côte d'Ivoire; 4Department of Molecular Medicine and Hematology, National Health Laboratory Service, Johannesburg, South Africa; 5Center for Global Health, Division of Global HIV/AIDS, CDC, Lilongwe, Malawi; 6Center for Global Health, Division of Global HIV/AIDS, CDC, Nairobi, Kenya; 7Center for Global Health, Division of Global HIV/AIDS, CDC, Pretoria, South Africa; 8Central Public Health Laboratories, Kampala, Uganda; 9Namibia Institute of Pathology, Windhoek, Namibia; 10Center for Global Health, Division of Global HIV/AIDS, CDC, Kampala, Uganda; 11Center for Global Health, Division of Global HIV/AIDS, CDC, Dar es Salaam, Tanzania; 12National Department of Health, Pretoria, South Africa.
Corresponding author: Shirley Lecher, slecher@cdc.gov, 404-639-6315.
.png)
No hay comentarios:
Publicar un comentario